Part,  Chapter, Paragraph

1   II,     5.  5.  3|        certain therapeutic options, non-compliance, etc..~According to a literature
2   II,     5.  5.  3|          enhance compliance, etc.), non-compliance, difficulties in implementing
3   II,     5.  5.  3|    reflected in European guidelines~Non-compliance~Another key factor responsible
4   II,     5.  5.  3|          for a treatment gap is the non-compliance of people with schizophrenia
5   II,     5.  5.  3| non-adherence to medication. Median non-compliance rates are 50%, thus being
6   II,     5.  5.  3|           drugs (Kahn et al, 2008). Non-compliance does not necessarily mean “